Infiltrating renal pelvis/ureter urothelial carcinoma

Summary

Infiltrating renal pelvis/ureter urothelial carcinoma (MONDO:0004010) is a cancer and 1 clinical trial. Top therapeutic interventions include carboplatin. A subtype of infiltrating urothelial carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	infiltrating renal pelvis/ureter urothelial carcinoma
Mondo ID	MONDO:0004010
NCIT	C39879
UMLS	C1512750
MedGen	268273
Anatomy (UBERON)	UBERON:0036295
Is cancer (heuristic)	yes

Also known as: infiltrating renal pelvis and ureter transitional cell carcinoma · infiltrating renal pelvis and ureter urothelial carcinoma · infiltrating ureter transitional cell carcinoma

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant urinary system neoplasm › infiltrating urothelial carcinoma › infiltrating renal pelvis/ureter urothelial carcinoma

Related subtypes (1): infiltrating bladder urothelial carcinoma

Subtypes (2): infiltrating renal pelvis transitional cell carcinoma, infiltrating ureter transitional cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04871529	PHASE2	TERMINATED	Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	1